Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma

Published:2017-10-27 Issue:24 Volume:1 Page:2138-2146
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kim Young Ae¹,Byun Ja Min²³,Park Keeho¹,Bae Gi Hwan¹,Lee Dukhyoung⁴,Kim Dong Sook⁵,Yoon Sung-Soo³,Koh Youngil³

Affiliation:

1. Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang-si, Korea;

2. Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea;

3. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea;

4. National Cancer Control Institute, National Cancer Center, Goyang-si, Korea; and

5. Health Insurance Review Agency, Wonju-si, Korea

Abstract

Key Points Etoposide addition/chemo-intensification has little role in first-line treatment of PTCL in Asian populations, regardless of subtype or age. Upfront hematopoietic stem-cell transplantation as consolidation seems like a legitimate choice in patients with PTCL.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/24/2138/879011/advances010819.pdf

Reference26 articles.

1. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

2. T-cell non-Hodgkin lymphoma;Rizvi;Blood,2006

3. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives);Coiffier;Ann Oncol,1990

4. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350;Mahadevan;Cancer,2013

5. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry;Ellin;Blood,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas;European Journal of Haematology;2023-10-16

2. Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma;Clinical and Experimental Medicine;2023-09-27

3. Breaking Spatiotemporal Barriers of Immunogenic Chemotherapy via an Endoplasmic Reticulum Membrane-Assisted Liposomal Drug Delivery;ACS Nano;2023-05-19

4. The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients;Asia-Pacific Journal of Clinical Oncology;2022-07-12

5. Peripheral T-Cell Lymphomas: Therapeutic Approaches;Cancers;2022-05-08